BenevolentAI S.A.
BenevolentAI S.A. (BAI.AS) Stock Competitors & Peer Comparison
See (BAI.AS) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BAI.AS | €0.08 | +0.00% | 11.2M | -0.13 | -€0.64 | N/A |
| UCB.BR | €264.50 | +2.32% | 51B | 33.35 | €8.03 | +0.45% |
| ARGX.BR | €647.20 | +4.25% | 40B | 37.90 | €17.04 | N/A |
| TUB.BR | €219.50 | +3.54% | 9.7B | 104.31 | €2.09 | +0.41% |
| ABVX.PA | €101.40 | +8.33% | 8.1B | -21.12 | -€4.83 | N/A |
| GLPG.AS | €25.60 | -2.22% | 1.7B | 5.35 | €4.85 | N/A |
| NANO.PA | €27.45 | +6.19% | 1.4B | -26.56 | -€1.09 | N/A |
| PHARM.AS | €1.43 | -0.07% | 1B | -145.90 | -€0.01 | N/A |
| MEDCL.PA | €23.10 | +2.48% | 835.1M | -38.13 | -€0.61 | N/A |
| IVA.PA | €4.72 | -0.63% | 636.2M | -2.41 | -€1.90 | N/A |
Stock Comparison
BAI.AS vs UCB.BR Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, UCB.BR has a market cap of 51B. Regarding current trading prices, BAI.AS is priced at €0.08, while UCB.BR trades at €264.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas UCB.BR's P/E ratio is 33.35. In terms of profitability, BAI.AS's ROE is -0.51%, compared to UCB.BR's ROE of +0.15%. Regarding short-term risk, BAI.AS is more volatile compared to UCB.BR. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check UCB.BR's competition here
BAI.AS vs ARGX.BR Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ARGX.BR has a market cap of 40B. Regarding current trading prices, BAI.AS is priced at €0.08, while ARGX.BR trades at €647.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ARGX.BR's P/E ratio is 37.90. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ARGX.BR's ROE of +0.17%. Regarding short-term risk, BAI.AS is more volatile compared to ARGX.BR. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check ARGX.BR's competition here
BAI.AS vs TUB.BR Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, TUB.BR has a market cap of 9.7B. Regarding current trading prices, BAI.AS is priced at €0.08, while TUB.BR trades at €219.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas TUB.BR's P/E ratio is 104.31. In terms of profitability, BAI.AS's ROE is -0.51%, compared to TUB.BR's ROE of +0.05%. Regarding short-term risk, BAI.AS is more volatile compared to TUB.BR. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check TUB.BR's competition here
BAI.AS vs ABVX.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ABVX.PA has a market cap of 8.1B. Regarding current trading prices, BAI.AS is priced at €0.08, while ABVX.PA trades at €101.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ABVX.PA's P/E ratio is -21.12. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ABVX.PA's ROE of -1.65%. Regarding short-term risk, BAI.AS is more volatile compared to ABVX.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check ABVX.PA's competition here
BAI.AS vs GLPG.AS Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, GLPG.AS has a market cap of 1.7B. Regarding current trading prices, BAI.AS is priced at €0.08, while GLPG.AS trades at €25.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas GLPG.AS's P/E ratio is 5.35. In terms of profitability, BAI.AS's ROE is -0.51%, compared to GLPG.AS's ROE of +0.11%. Regarding short-term risk, BAI.AS is more volatile compared to GLPG.AS. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check GLPG.AS's competition here
BAI.AS vs NANO.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, NANO.PA has a market cap of 1.4B. Regarding current trading prices, BAI.AS is priced at €0.08, while NANO.PA trades at €27.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas NANO.PA's P/E ratio is -26.56. In terms of profitability, BAI.AS's ROE is -0.51%, compared to NANO.PA's ROE of +0.77%. Regarding short-term risk, BAI.AS is more volatile compared to NANO.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check NANO.PA's competition here
BAI.AS vs PHARM.AS Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, PHARM.AS has a market cap of 1B. Regarding current trading prices, BAI.AS is priced at €0.08, while PHARM.AS trades at €1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas PHARM.AS's P/E ratio is -145.90. In terms of profitability, BAI.AS's ROE is -0.51%, compared to PHARM.AS's ROE of +0.01%. Regarding short-term risk, BAI.AS is more volatile compared to PHARM.AS. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check PHARM.AS's competition here
BAI.AS vs MEDCL.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, MEDCL.PA has a market cap of 835.1M. Regarding current trading prices, BAI.AS is priced at €0.08, while MEDCL.PA trades at €23.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas MEDCL.PA's P/E ratio is -38.13. In terms of profitability, BAI.AS's ROE is -0.51%, compared to MEDCL.PA's ROE of +0.85%. Regarding short-term risk, BAI.AS is more volatile compared to MEDCL.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check MEDCL.PA's competition here
BAI.AS vs IVA.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, IVA.PA has a market cap of 636.2M. Regarding current trading prices, BAI.AS is priced at €0.08, while IVA.PA trades at €4.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas IVA.PA's P/E ratio is -2.41. In terms of profitability, BAI.AS's ROE is -0.51%, compared to IVA.PA's ROE of +5.36%. Regarding short-term risk, BAI.AS is more volatile compared to IVA.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check IVA.PA's competition here
BAI.AS vs DBV.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, DBV.PA has a market cap of 634.1M. Regarding current trading prices, BAI.AS is priced at €0.08, while DBV.PA trades at €3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas DBV.PA's P/E ratio is -4.08. In terms of profitability, BAI.AS's ROE is -0.51%, compared to DBV.PA's ROE of -1.89%. Regarding short-term risk, BAI.AS is more volatile compared to DBV.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check DBV.PA's competition here
BAI.AS vs GTBP.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, GTBP.PA has a market cap of 626.7M. Regarding current trading prices, BAI.AS is priced at €0.08, while GTBP.PA trades at €280.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas GTBP.PA's P/E ratio is -4.10. In terms of profitability, BAI.AS's ROE is -0.51%, compared to GTBP.PA's ROE of -8.81%. Regarding short-term risk, BAI.AS is less volatile compared to GTBP.PA. This indicates potentially lower risk in terms of short-term price fluctuations for BAI.AS.Check GTBP.PA's competition here
BAI.AS vs VLA.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, VLA.PA has a market cap of 485.6M. Regarding current trading prices, BAI.AS is priced at €0.08, while VLA.PA trades at €2.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas VLA.PA's P/E ratio is -4.15. In terms of profitability, BAI.AS's ROE is -0.51%, compared to VLA.PA's ROE of -0.75%. Regarding short-term risk, BAI.AS is more volatile compared to VLA.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check VLA.PA's competition here
BAI.AS vs GNFT.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, GNFT.PA has a market cap of 430.4M. Regarding current trading prices, BAI.AS is priced at €0.08, while GNFT.PA trades at €8.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas GNFT.PA's P/E ratio is -11.06. In terms of profitability, BAI.AS's ROE is -0.51%, compared to GNFT.PA's ROE of -0.64%. Regarding short-term risk, BAI.AS is more volatile compared to GNFT.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check GNFT.PA's competition here
BAI.AS vs ORY.MC Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ORY.MC has a market cap of 220M. Regarding current trading prices, BAI.AS is priced at €0.08, while ORY.MC trades at €2.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ORY.MC's P/E ratio is -93.00. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ORY.MC's ROE of -0.03%. Regarding short-term risk, BAI.AS is more volatile compared to ORY.MC. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check ORY.MC's competition here
BAI.AS vs ALCLS.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ALCLS.PA has a market cap of 217.7M. Regarding current trading prices, BAI.AS is priced at €0.08, while ALCLS.PA trades at €3.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ALCLS.PA's P/E ratio is -5.10. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ALCLS.PA's ROE of -0.70%. Regarding short-term risk, BAI.AS is more volatile compared to ALCLS.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check ALCLS.PA's competition here
BAI.AS vs ONWD.BR Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ONWD.BR has a market cap of 152.4M. Regarding current trading prices, BAI.AS is priced at €0.08, while ONWD.BR trades at €3.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ONWD.BR's P/E ratio is -4.61. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ONWD.BR's ROE of -1.02%. Regarding short-term risk, BAI.AS is more volatile compared to ONWD.BR. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check ONWD.BR's competition here
BAI.AS vs HYL.BR Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, HYL.BR has a market cap of 142.8M. Regarding current trading prices, BAI.AS is priced at €0.08, while HYL.BR trades at €4.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas HYL.BR's P/E ratio is -21.25. In terms of profitability, BAI.AS's ROE is -0.51%, compared to HYL.BR's ROE of -0.17%. Regarding short-term risk, BAI.AS is more volatile compared to HYL.BR. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check HYL.BR's competition here
BAI.AS vs ALSEN.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ALSEN.PA has a market cap of 130.1M. Regarding current trading prices, BAI.AS is priced at €0.08, while ALSEN.PA trades at €0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ALSEN.PA's P/E ratio is -4.25. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ALSEN.PA's ROE of -0.58%. Regarding short-term risk, BAI.AS is more volatile compared to ALSEN.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check ALSEN.PA's competition here
BAI.AS vs ABNX.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ABNX.PA has a market cap of 129.7M. Regarding current trading prices, BAI.AS is priced at €0.08, while ABNX.PA trades at €3.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ABNX.PA's P/E ratio is -28.31. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ABNX.PA's ROE of -1.15%. Regarding short-term risk, BAI.AS is more volatile compared to ABNX.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check ABNX.PA's competition here
BAI.AS vs TNG.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, TNG.PA has a market cap of 110.5M. Regarding current trading prices, BAI.AS is priced at €0.08, while TNG.PA trades at €0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas TNG.PA's P/E ratio is -2.95. In terms of profitability, BAI.AS's ROE is -0.51%, compared to TNG.PA's ROE of -0.64%. Regarding short-term risk, BAI.AS is more volatile compared to TNG.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check TNG.PA's competition here
BAI.AS vs IPH.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, IPH.PA has a market cap of 105.4M. Regarding current trading prices, BAI.AS is priced at €0.08, while IPH.PA trades at €1.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas IPH.PA's P/E ratio is -2.04. In terms of profitability, BAI.AS's ROE is -0.51%, compared to IPH.PA's ROE of +5.94%. Regarding short-term risk, BAI.AS is more volatile compared to IPH.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check IPH.PA's competition here
BAI.AS vs ADOC.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ADOC.PA has a market cap of 95.2M. Regarding current trading prices, BAI.AS is priced at €0.08, while ADOC.PA trades at €4.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ADOC.PA's P/E ratio is -5.18. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ADOC.PA's ROE of +5.24%. Regarding short-term risk, BAI.AS is more volatile compared to ADOC.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check ADOC.PA's competition here
BAI.AS vs MAAT.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, MAAT.PA has a market cap of 87.4M. Regarding current trading prices, BAI.AS is priced at €0.08, while MAAT.PA trades at €5.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas MAAT.PA's P/E ratio is -2.69. In terms of profitability, BAI.AS's ROE is -0.51%, compared to MAAT.PA's ROE of -3.34%. Regarding short-term risk, BAI.AS is more volatile compared to MAAT.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check MAAT.PA's competition here
BAI.AS vs OSE.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, OSE.PA has a market cap of 73.4M. Regarding current trading prices, BAI.AS is priced at €0.08, while OSE.PA trades at €3.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas OSE.PA's P/E ratio is -13.63. In terms of profitability, BAI.AS's ROE is -0.51%, compared to OSE.PA's ROE of -0.61%. Regarding short-term risk, BAI.AS is more volatile compared to OSE.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check OSE.PA's competition here
BAI.AS vs ERYP.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ERYP.PA has a market cap of 48.7M. Regarding current trading prices, BAI.AS is priced at €0.08, while ERYP.PA trades at €0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ERYP.PA's P/E ratio is -80.10. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ERYP.PA's ROE of -0.96%. Regarding short-term risk, BAI.AS is more volatile compared to ERYP.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check ERYP.PA's competition here
BAI.AS vs ALVIO.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ALVIO.PA has a market cap of 42.3M. Regarding current trading prices, BAI.AS is priced at €0.08, while ALVIO.PA trades at €0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ALVIO.PA's P/E ratio is -1.34. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ALVIO.PA's ROE of +1.46%. Regarding short-term risk, BAI.AS is more volatile compared to ALVIO.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check ALVIO.PA's competition here
BAI.AS vs VVY.AS Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, VVY.AS has a market cap of 39.1M. Regarding current trading prices, BAI.AS is priced at €0.08, while VVY.AS trades at €1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas VVY.AS's P/E ratio is -2.75. In terms of profitability, BAI.AS's ROE is -0.51%, compared to VVY.AS's ROE of -2.26%. Regarding short-term risk, BAI.AS is more volatile compared to VVY.AS. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check VVY.AS's competition here
BAI.AS vs COX.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, COX.PA has a market cap of 29M. Regarding current trading prices, BAI.AS is priced at €0.08, while COX.PA trades at €0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas COX.PA's P/E ratio is -0.46. In terms of profitability, BAI.AS's ROE is -0.51%, compared to COX.PA's ROE of -0.43%. Regarding short-term risk, BAI.AS is more volatile compared to COX.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check COX.PA's competition here
BAI.AS vs ALVAL.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ALVAL.PA has a market cap of 25.8M. Regarding current trading prices, BAI.AS is priced at €0.08, while ALVAL.PA trades at €1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ALVAL.PA's P/E ratio is -2.32. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ALVAL.PA's ROE of -1.09%. Regarding short-term risk, BAI.AS is more volatile compared to ALVAL.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check ALVAL.PA's competition here
BAI.AS vs FALG.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, FALG.PA has a market cap of 24M. Regarding current trading prices, BAI.AS is priced at €0.08, while FALG.PA trades at €0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas FALG.PA's P/E ratio is -2.33. In terms of profitability, BAI.AS's ROE is -0.51%, compared to FALG.PA's ROE of -0.39%. Regarding short-term risk, BAI.AS is more volatile compared to FALG.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check FALG.PA's competition here
BAI.AS vs DMSIM.BR Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, DMSIM.BR has a market cap of 23.1M. Regarding current trading prices, BAI.AS is priced at €0.08, while DMSIM.BR trades at €0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas DMSIM.BR's P/E ratio is 0.09. In terms of profitability, BAI.AS's ROE is -0.51%, compared to DMSIM.BR's ROE of -0.57%. Regarding short-term risk, BAI.AS is more volatile compared to DMSIM.BR. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check DMSIM.BR's competition here
BAI.AS vs ALGEN.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ALGEN.PA has a market cap of 23M. Regarding current trading prices, BAI.AS is priced at €0.08, while ALGEN.PA trades at €2.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ALGEN.PA's P/E ratio is 14.00. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ALGEN.PA's ROE of +0.07%. Regarding short-term risk, BAI.AS is more volatile compared to ALGEN.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check ALGEN.PA's competition here
BAI.AS vs ALDVI.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ALDVI.PA has a market cap of 21.9M. Regarding current trading prices, BAI.AS is priced at €0.08, while ALDVI.PA trades at €1.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ALDVI.PA's P/E ratio is -1.90. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ALDVI.PA's ROE of +0.44%. Regarding short-term risk, BAI.AS is more volatile compared to ALDVI.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check ALDVI.PA's competition here
BAI.AS vs AELIS.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, AELIS.PA has a market cap of 18.2M. Regarding current trading prices, BAI.AS is priced at €0.08, while AELIS.PA trades at €1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas AELIS.PA's P/E ratio is -2.22. In terms of profitability, BAI.AS's ROE is -0.51%, compared to AELIS.PA's ROE of -1.01%. Regarding short-term risk, BAI.AS is more volatile compared to AELIS.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check AELIS.PA's competition here
BAI.AS vs POXEL.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, POXEL.PA has a market cap of 17.1M. Regarding current trading prices, BAI.AS is priced at €0.08, while POXEL.PA trades at €0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas POXEL.PA's P/E ratio is -1.23. In terms of profitability, BAI.AS's ROE is -0.51%, compared to POXEL.PA's ROE of +0.23%. Regarding short-term risk, BAI.AS is more volatile compared to POXEL.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check POXEL.PA's competition here
BAI.AS vs SIGHT.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, SIGHT.PA has a market cap of 16.5M. Regarding current trading prices, BAI.AS is priced at €0.08, while SIGHT.PA trades at €0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas SIGHT.PA's P/E ratio is -0.67. In terms of profitability, BAI.AS's ROE is -0.51%, compared to SIGHT.PA's ROE of +0.42%. Regarding short-term risk, BAI.AS is more volatile compared to SIGHT.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check SIGHT.PA's competition here
BAI.AS vs ALPHE.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ALPHE.PA has a market cap of 15.8M. Regarding current trading prices, BAI.AS is priced at €0.08, while ALPHE.PA trades at €2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ALPHE.PA's P/E ratio is -2.67. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ALPHE.PA's ROE of -0.64%. Regarding short-term risk, BAI.AS is more volatile compared to ALPHE.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check ALPHE.PA's competition here
BAI.AS vs CYAD.BR Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, CYAD.BR has a market cap of 14.1M. Regarding current trading prices, BAI.AS is priced at €0.08, while CYAD.BR trades at €0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas CYAD.BR's P/E ratio is -0.22. In terms of profitability, BAI.AS's ROE is -0.51%, compared to CYAD.BR's ROE of +0.67%. Regarding short-term risk, BAI.AS is more volatile compared to CYAD.BR. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check CYAD.BR's competition here
BAI.AS vs ALNFL.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ALNFL.PA has a market cap of 13.7M. Regarding current trading prices, BAI.AS is priced at €0.08, while ALNFL.PA trades at €1.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ALNFL.PA's P/E ratio is -3.85. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ALNFL.PA's ROE of -2.25%. Regarding short-term risk, BAI.AS is more volatile compared to ALNFL.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check ALNFL.PA's competition here
BAI.AS vs ALVET.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ALVET.PA has a market cap of 10M. Regarding current trading prices, BAI.AS is priced at €0.08, while ALVET.PA trades at €0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ALVET.PA's P/E ratio is -0.17. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ALVET.PA's ROE of -0.23%. Regarding short-term risk, BAI.AS is more volatile compared to ALVET.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check ALVET.PA's competition here
BAI.AS vs APM.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, APM.PA has a market cap of 8.8M. Regarding current trading prices, BAI.AS is priced at €0.08, while APM.PA trades at €3.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas APM.PA's P/E ratio is -0.71. In terms of profitability, BAI.AS's ROE is -0.51%, compared to APM.PA's ROE of -0.14%. Regarding short-term risk, BAI.AS is less volatile compared to APM.PA. This indicates potentially lower risk in terms of short-term price fluctuations for BAI.AS.Check APM.PA's competition here
BAI.AS vs ALPAT.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ALPAT.PA has a market cap of 8.7M. Regarding current trading prices, BAI.AS is priced at €0.08, while ALPAT.PA trades at €7.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ALPAT.PA's P/E ratio is 9.25. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ALPAT.PA's ROE of +0.11%. Regarding short-term risk, BAI.AS is more volatile compared to ALPAT.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check ALPAT.PA's competition here
BAI.AS vs ALTME.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ALTME.PA has a market cap of 6.5M. Regarding current trading prices, BAI.AS is priced at €0.08, while ALTME.PA trades at €0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ALTME.PA's P/E ratio is -1.38. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ALTME.PA's ROE of -8.77%. Regarding short-term risk, BAI.AS is more volatile compared to ALTME.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check ALTME.PA's competition here
BAI.AS vs ALQGC.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ALQGC.PA has a market cap of 5M. Regarding current trading prices, BAI.AS is priced at €0.08, while ALQGC.PA trades at €0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ALQGC.PA's P/E ratio is -0.09. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ALQGC.PA's ROE of +8.81%. Regarding short-term risk, BAI.AS is more volatile compared to ALQGC.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check ALQGC.PA's competition here
BAI.AS vs LYS.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, LYS.PA has a market cap of 4.9M. Regarding current trading prices, BAI.AS is priced at €0.08, while LYS.PA trades at €0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas LYS.PA's P/E ratio is -0.64. In terms of profitability, BAI.AS's ROE is -0.51%, compared to LYS.PA's ROE of -11.30%. Regarding short-term risk, BAI.AS is more volatile compared to LYS.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check LYS.PA's competition here
BAI.AS vs ALHYG.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ALHYG.PA has a market cap of 3.9M. Regarding current trading prices, BAI.AS is priced at €0.08, while ALHYG.PA trades at €0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ALHYG.PA's P/E ratio is -0.26. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ALHYG.PA's ROE of -6.80%. Regarding short-term risk, BAI.AS is more volatile compared to ALHYG.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check ALHYG.PA's competition here
BAI.AS vs ALACT.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ALACT.PA has a market cap of 3.9M. Regarding current trading prices, BAI.AS is priced at €0.08, while ALACT.PA trades at €0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ALACT.PA's P/E ratio is -0.22. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ALACT.PA's ROE of +4.93%. Regarding short-term risk, BAI.AS is more volatile compared to ALACT.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check ALACT.PA's competition here
BAI.AS vs ALMDP.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ALMDP.PA has a market cap of 1.8M. Regarding current trading prices, BAI.AS is priced at €0.08, while ALMDP.PA trades at €0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ALMDP.PA's P/E ratio is -0.59. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ALMDP.PA's ROE of +1.42%. Regarding short-term risk, BAI.AS is more volatile compared to ALMDP.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check ALMDP.PA's competition here
BAI.AS vs BIOS.BR Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, BIOS.BR has a market cap of 1.5M. Regarding current trading prices, BAI.AS is priced at €0.08, while BIOS.BR trades at €0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas BIOS.BR's P/E ratio is -0.11. In terms of profitability, BAI.AS's ROE is -0.51%, compared to BIOS.BR's ROE of -1.64%. Regarding short-term risk, BAI.AS is more volatile compared to BIOS.BR. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check BIOS.BR's competition here
BAI.AS vs ALINT.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ALINT.PA has a market cap of 1.2M. Regarding current trading prices, BAI.AS is priced at €0.08, while ALINT.PA trades at €0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ALINT.PA's P/E ratio is -4.67. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ALINT.PA's ROE of -1.48%. Regarding short-term risk, BAI.AS is more volatile compared to ALINT.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check ALINT.PA's competition here
BAI.AS vs ALDEI.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ALDEI.PA has a market cap of 1.1M. Regarding current trading prices, BAI.AS is priced at €0.08, while ALDEI.PA trades at €0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ALDEI.PA's P/E ratio is -0.11. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ALDEI.PA's ROE of +0.61%. Regarding short-term risk, BAI.AS is less volatile compared to ALDEI.PA. This indicates potentially lower risk in terms of short-term price fluctuations for BAI.AS.Check ALDEI.PA's competition here
BAI.AS vs GNRO.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, GNRO.PA has a market cap of 908.2K. Regarding current trading prices, BAI.AS is priced at €0.08, while GNRO.PA trades at €0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas GNRO.PA's P/E ratio is -0.05. In terms of profitability, BAI.AS's ROE is -0.51%, compared to GNRO.PA's ROE of +2.40%. Regarding short-term risk, BAI.AS is more volatile compared to GNRO.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check GNRO.PA's competition here
BAI.AS vs OVXA.IR Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, OVXA.IR has a market cap of 856.4K. Regarding current trading prices, BAI.AS is priced at €0.08, while OVXA.IR trades at €0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas OVXA.IR's P/E ratio is -0.21. In terms of profitability, BAI.AS's ROE is -0.51%, compared to OVXA.IR's ROE of -0.93%. Regarding short-term risk, BAI.AS is more volatile compared to OVXA.IR. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check OVXA.IR's competition here
BAI.AS vs OXUR.BR Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, OXUR.BR has a market cap of 392.6K. Regarding current trading prices, BAI.AS is priced at €0.08, while OXUR.BR trades at €0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas OXUR.BR's P/E ratio is N/A. In terms of profitability, BAI.AS's ROE is -0.51%, compared to OXUR.BR's ROE of -0.17%. Regarding short-term risk, BAI.AS is more volatile compared to OXUR.BR. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check OXUR.BR's competition here
BAI.AS vs ALBPS.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ALBPS.PA has a market cap of 390.3K. Regarding current trading prices, BAI.AS is priced at €0.08, while ALBPS.PA trades at €0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ALBPS.PA's P/E ratio is -0.05. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ALBPS.PA's ROE of +0.92%. Regarding short-term risk, BAI.AS is more volatile compared to ALBPS.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check ALBPS.PA's competition here
BAI.AS vs ALPHA.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ALPHA.PA has a market cap of 1.2K. Regarding current trading prices, BAI.AS is priced at €0.08, while ALPHA.PA trades at €0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ALPHA.PA's P/E ratio is -0.00. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ALPHA.PA's ROE of +0.83%. Regarding short-term risk, BAI.AS is less volatile compared to ALPHA.PA. This indicates potentially lower risk in terms of short-term price fluctuations for BAI.AS.Check ALPHA.PA's competition here
BAI.AS vs ALNEV.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ALNEV.PA has a market cap of 286. Regarding current trading prices, BAI.AS is priced at €0.08, while ALNEV.PA trades at €0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ALNEV.PA's P/E ratio is N/A. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ALNEV.PA's ROE of -1.06%. Regarding short-term risk, BAI.AS is less volatile compared to ALNEV.PA. This indicates potentially lower risk in terms of short-term price fluctuations for BAI.AS.Check ALNEV.PA's competition here
BAI.AS vs ORPH.IR Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ORPH.IR has a market cap of 0. Regarding current trading prices, BAI.AS is priced at €0.08, while ORPH.IR trades at €0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ORPH.IR's P/E ratio is N/A. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ORPH.IR's ROE of +0.27%. Regarding short-term risk, BAI.AS is more volatile compared to ORPH.IR. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check ORPH.IR's competition here
BAI.AS vs BOTHE.BR Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, BOTHE.BR has a market cap of 0. Regarding current trading prices, BAI.AS is priced at €0.08, while BOTHE.BR trades at €0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas BOTHE.BR's P/E ratio is -0.38. In terms of profitability, BAI.AS's ROE is -0.51%, compared to BOTHE.BR's ROE of +2.97%. Regarding short-term risk, BAI.AS is less volatile compared to BOTHE.BR. This indicates potentially lower risk in terms of short-term price fluctuations for BAI.AS.Check BOTHE.BR's competition here
BAI.AS vs GLPG.BR Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, GLPG.BR has a market cap of 0. Regarding current trading prices, BAI.AS is priced at €0.08, while GLPG.BR trades at €15.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas GLPG.BR's P/E ratio is N/A. In terms of profitability, BAI.AS's ROE is -0.51%, compared to GLPG.BR's ROE of -0.10%. Regarding short-term risk, BAI.AS is more volatile compared to GLPG.BR. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check GLPG.BR's competition here
BAI.AS vs ASIT.BR Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ASIT.BR has a market cap of 0. Regarding current trading prices, BAI.AS is priced at €0.08, while ASIT.BR trades at €0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ASIT.BR's P/E ratio is -32.71. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ASIT.BR's ROE of +0.38%. Regarding short-term risk, BAI.AS is more volatile compared to ASIT.BR. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check ASIT.BR's competition here
BAI.AS vs ALNOX.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ALNOX.PA has a market cap of 0. Regarding current trading prices, BAI.AS is priced at €0.08, while ALNOX.PA trades at €0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ALNOX.PA's P/E ratio is -0.19. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ALNOX.PA's ROE of -2.36%. Regarding short-term risk, BAI.AS is more volatile compared to ALNOX.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check ALNOX.PA's competition here
BAI.AS vs ADVIC.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ADVIC.PA has a market cap of 0. Regarding current trading prices, BAI.AS is priced at €0.08, while ADVIC.PA trades at €6.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ADVIC.PA's P/E ratio is -3.67. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ADVIC.PA's ROE of +0.44%. Regarding short-term risk, BAI.AS is more volatile compared to ADVIC.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check ADVIC.PA's competition here
BAI.AS vs ACPH.BR Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ACPH.BR has a market cap of 0. Regarding current trading prices, BAI.AS is priced at €0.08, while ACPH.BR trades at €0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ACPH.BR's P/E ratio is -1.40. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ACPH.BR's ROE of -1.55%. Regarding short-term risk, BAI.AS is more volatile compared to ACPH.BR. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check ACPH.BR's competition here
BAI.AS vs VLAP.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, VLAP.PA has a market cap of 0. Regarding current trading prices, BAI.AS is priced at €0.08, while VLAP.PA trades at €0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas VLAP.PA's P/E ratio is -0.10. In terms of profitability, BAI.AS's ROE is -0.51%, compared to VLAP.PA's ROE of -0.75%. Regarding short-term risk, BAI.AS is more volatile compared to VLAP.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check VLAP.PA's competition here
BAI.AS vs ALIMM.BR Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ALIMM.BR has a market cap of 0. Regarding current trading prices, BAI.AS is priced at €0.08, while ALIMM.BR trades at €0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ALIMM.BR's P/E ratio is -2.23. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ALIMM.BR's ROE of -0.39%. Regarding short-term risk, BAI.AS is more volatile compared to ALIMM.BR. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check ALIMM.BR's competition here
BAI.AS vs GKTX.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, GKTX.PA has a market cap of 0. Regarding current trading prices, BAI.AS is priced at €0.08, while GKTX.PA trades at €3.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas GKTX.PA's P/E ratio is -2.56. In terms of profitability, BAI.AS's ROE is -0.51%, compared to GKTX.PA's ROE of -2.26%. Regarding short-term risk, BAI.AS is more volatile compared to GKTX.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check GKTX.PA's competition here
BAI.AS vs ALONC.PA Comparison April 2026
BAI.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAI.AS stands at 11.2M. In comparison, ALONC.PA has a market cap of 0. Regarding current trading prices, BAI.AS is priced at €0.08, while ALONC.PA trades at €14.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAI.AS currently has a P/E ratio of -0.13, whereas ALONC.PA's P/E ratio is 63.25. In terms of profitability, BAI.AS's ROE is -0.51%, compared to ALONC.PA's ROE of -0.09%. Regarding short-term risk, BAI.AS is more volatile compared to ALONC.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BAI.AS.Check ALONC.PA's competition here